Details:
ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm. The vaccine will be administered intramuscularly (IM).
Lead Product(s): ChAdOx1 biEBOV
Therapeutic Area: Infections and Infectious Diseases Product Name: ChAdOx1 biEBOV
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: University of Oxford
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
India's drug controller had in January this year given permission to Bharat Biotech to conduct standalone on its Covid-19 intranasal vaccine. The phase 3 trials of the intranasal vaccine candidate BBV154 (Chad SARS-COV-2) are underway and likely to be completed soon.
Lead Product(s): Chad SARS-COV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
Orphan drug designation is based on Phase I study of ZY19489, a novel antimalarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug-resistant strains.
Lead Product(s): ZY-19489
Therapeutic Area: Infections and Infectious Diseases Product Name: ZY-19489
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
BWC0977 is a highly potent, intravenous broad-spectrum antibiotic with the potential for oral administration, for the treatment of serious multi drug resistant (MDR) gram-negative infections.
Lead Product(s): BWC0977
Therapeutic Area: Infections and Infectious Diseases Product Name: BWC0977
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
Bharat Biotech's intranasal vaccine, BBV154, received regulatory approval for second phase trials in August. The trials will begin in a couple of weeks after permission is granted by the committee.
Lead Product(s): Chad SARS-COV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: AIIMS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. The Phase-1 trials will be conducted in Saint Louis University's Vaccine and Treatment Evaluation Unit.
Lead Product(s): BBV154
Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.
Lead Product(s): VXA-CoV2-1
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Vaxart
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020
Details:
CEPI will fund the consortium for vaccine manufacturing and clinical development of a 2-dose live-inactivated vaccine (BBV87) against Chikungunya. The partnering agreement will finance a multi-centre Phase 2/3 adaptive clinical trial to be conducted by IVI.
Lead Product(s): BBV87
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $14.1 million Upfront Cash: Undisclosed
Deal Type: Funding May 03, 2020
Details:
This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development.
Lead Product(s): GYROX-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Tokyo Edge Capital
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2020